Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy

11 Jun 2023

Abstract excerpt

Glucosylceramidase beta 1 (GBA1) variants have attracted enormous attention as the most promising and important genetic candidates for precision medicine in Parkinson's disease (PD). A substantial correlation between GBA1 genotypes and PD phenotypes could inform the prediction of disease progression and promote the development of a preventive intervention for individuals at a higher risk of a worse disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbohydrate Chemistry and Synthesis
Share to Cellular transport and secretion
Share to Lysosomal Storage Disorders Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37302978
DOI: 10.14802/jmd.23023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted TherapyPMID 37302978Read ↗

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.Semantic proximity Read ↗

Multi-omics insights into GBA1-associated Parkinson's disease: interplay of genomics, transcriptomics, proteomics, and lipidomics.Semantic proximity Read ↗

Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.Semantic proximity Read ↗

GBA Variants and Parkinson Disease: Mechanisms and Treatments.Semantic proximity Read ↗

The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson's Disease: a New Genetic State of the Art.Semantic proximity Read ↗

GBA1-Associated Parkinson's Disease Is a Distinct Entity.Semantic proximity Read ↗

Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.Semantic proximity Read ↗

GBA1-associated parkinsonism: new insights and therapeutic opportunitiesSemantic proximity Read ↗

Glucocerebrosidase mutations and Parkinson disease.Semantic proximity Read ↗

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic ImplicationsSemantic proximity Read ↗

Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.Semantic proximity Read ↗

A Global Perspective of GBA1-Related Parkinson's Disease: A Narrative Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.